<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965120</url>
  </required_header>
  <id_info>
    <org_study_id>CMP 3</org_study_id>
    <nct_id>NCT00965120</nct_id>
  </id_info>
  <brief_title>The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway</brief_title>
  <official_title>The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart attacks are usually caused by a blood clot blocking an artery supplying blood to the
      heart. Current treatments are designed to relieve this blockage as quickly as possible to
      minimize damage to the heart muscle. However in restoring the supply of blood local damage
      known as &quot;ischaemia-reperfusion injury&quot; may occur. The aim of this study is to assess how
      clot forming and clot dissolving pathways are affected during this process, and examine the
      role of a natural inflammatory hormone, bradykinin. This will help the investigators to
      understand the mechanism by which ischaemia-reperfusion injury may occur and to devise new
      treatments for heart attacks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forearm blood flow in response to vasodilators (ACh) and ischaemia reperfusion</measure>
    <time_frame>20 fixed timepoints during each study visit (3hrs)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in platelet-monocyte-binding after ischaemia reperfusion</measure>
    <time_frame>4 fixed timepoints during each study visit (3hrs)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Ischaemic Heart Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Forearm vascular study</intervention_name>
    <description>Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bradykinin receptor antagonist (HOE-140)</intervention_name>
    <description>Systemic infusion of bradykinin receptor antagonist (HOE-140).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Systemic infusion of placebo (saline).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy males between 18-65 years of ages

          -  non-smokers

        Exclusion Criteria:

          -  any concurrent illness or chronic medical condition

          -  concurrent use of vasoactive medication

          -  smoking history
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Newby, PhD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh K Kharbanda, PhD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh, 49 Little France Crescent</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christian M Pedersen, clinical research fellow</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>Ischaemia reperfusion</keyword>
  <keyword>Bradykinin</keyword>
  <keyword>Platelet activation</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Icatibant</mesh_term>
    <mesh_term>Bradykinin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

